دورية أكاديمية
أعرض في EDS

Letters to the editor: Nicotinic acetylcholine receptor ligands as potential targets for managing neuropathic pain induced by diabetic peripheral neuropathy.

التفاصيل البيبلوغرافية
العنوان: Letters to the editor: Nicotinic acetylcholine receptor ligands as potential targets for managing neuropathic pain induced by diabetic peripheral neuropathy.
المؤلفون: Westlake S; Basic Sciences Department, New York Institute of Technology College of Osteopathic Medicine at Arkansas State University, Jonesboro, AR, USA., Jones M; Basic Sciences Department, New York Institute of Technology College of Osteopathic Medicine at Arkansas State University, Jonesboro, AR, USA., Sharma KD; Department of Biological Sciences and Arkansas Biosciences Institute, Arkansas State University, Jonesboro, AR, USA., Xie JY; Basic Sciences Department, New York Institute of Technology College of Osteopathic Medicine at Arkansas State University, Jonesboro, AR, USA.
المصدر: ENeurologicalSci [eNeurologicalSci] 2022 Jul 02; Vol. 28, pp. 100416. Date of Electronic Publication: 2022 Jul 02 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101667077 Publication Model: eCollection Cited Medium: Internet ISSN: 2405-6502 (Electronic) Linking ISSN: 24056502 NLM ISO Abbreviation: eNeurologicalSci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2015]-
مستخلص: Diabetic peripheral neuropathy (DPN) is a medical condition that is progressively becoming more prevalent. The underlying cause of DPN is still unknown, although there have been several hypothesized mechanisms. There are current pharmaceutical treatments used to manage the pain, but their efficacy is largely unsatisfactory and are often associated with serious adverse effects. This review will explore the evidence of a new potential target for treating DPN, the ligands for nicotinic acetylcholine receptors (nAChRs), specifically α4ꞵ2 agonists and α9α10 antagonists.
Competing Interests: None of the authors has any conflict of interest.
(© 2022 The Authors.)
References: ACS Chem Neurosci. 2019 Oct 16;10(10):4328-4336. (PMID: 31411453)
Biomolecules. 2018 Dec 23;9(1):. (PMID: 30583611)
Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):E1825-E1832. (PMID: 28223528)
Neuroscience. 2018 Sep 1;387:135-148. (PMID: 28890048)
J Neurochem. 2012 Sep;122(6):1137-44. (PMID: 22774872)
Pain. 2014 Oct;155(10):1986-95. (PMID: 25008370)
Biochem Pharmacol. 2007 Oct 15;74(8):1253-62. (PMID: 17854775)
Eur J Pharmacol. 2011 Oct 1;668(1-2):155-62. (PMID: 21756895)
Br J Pharmacol. 2018 Jun;175(11):1915-1927. (PMID: 28662295)
Eur J Pharmacol. 1998 Apr 3;346(1):23-33. (PMID: 9617748)
Mar Drugs. 2019 Dec 21;18(1):. (PMID: 31877728)
FEBS Lett. 2018 Apr;592(7):1045-1062. (PMID: 29030971)
فهرسة مساهمة: Keywords: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CCL2, C-C motif ligand 2; CNS, central nervous system; DPN, diabetic peripheral neuropathy; DRG, dorsal root ganglia; Diabetic peripheral neuropathy; GABA, gamma aminobutyric acid; IC50, half-maximal inhibitory concentration; IFN-γ, interferon gamma; IL-ꞵ, interleukin-1ꞵ; Nicotinic acetylcholine receptor ligands; Novel pharmacological treatments; TNF-α, tumor necrosis factor-alpha; nAChR, nicotinic acetylcholine receptor
تواريخ الأحداث: Date Created: 20220720 Latest Revision: 20220721
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9287153
DOI: 10.1016/j.ensci.2022.100416
PMID: 35855978
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-6502
DOI:10.1016/j.ensci.2022.100416